Elalfy Hanan Youssef, Elsamkary Mahmoud A, Elridy Ahmed M Shafek, Saad Tarek M, Rashad Saad Mohamed, Fawzy Samah M
Al Dorra Subspecialty Ophthalmology Centre, Cairo 11751, Egypt.
Department of Ophthalmology, Ain Shams University, Cairo 11471, Egypt.
Int J Ophthalmol. 2020 Jul 18;13(7):1074-1078. doi: 10.18240/ijo.2020.07.09. eCollection 2020.
To evaluate the role of medical treatment in the management of inflammatory punctum stenosis guided by spectral domain anterior segment optical coherence tomography (OCT).
This prospective study included 60 patients complaining of epiphora due to inflammatory punctual stenosis. They were divided into two groups: Group A (30 patients) treated with a combination of preservative free hydrocortisone sodium phosphate 3.35 mg/mL eye drops, and preservative free artificial tears based on sodium hyaluronate, polyethylene and propylene Glycol; Group B (30 patients) treated with the same preservative free artificial tears only. Thirty normal subjects were included for comparison of pre-treatment anatomical parameters. Before starting treatment, all patients underwent anterior segment assessment including slit lamp examination, measurement of intraocular pressure (IOP), fluorescein dye disappearance test, and measurement of the outer punctum diameter (OPD) by Spectral domain anterior segment OCT. All assessments were repeated at each follow up done at 1 and 3mo later, together with subjective evaluation of patient's satisfaction of the treatment outcome by simple rating questionnaire.
Punctual diameter increased significantly with treatment in both groups (<0.0001); although the widening was more in Group A as compared to group B (16.2% 8% of the original punctual size, mean difference of 28.933 µm, =0.0076). Subjective satisfaction with treatment outcome was also better in group A (70% 40%, Chi-square =0.0397).
A combination of preservative free steroid eye drops and artificial tears causes significant widening of inflammed stenotic punctae and improvement of the associated epiphora.
评估在频域眼前节光学相干断层扫描(OCT)引导下药物治疗在炎性泪点狭窄管理中的作用。
这项前瞻性研究纳入了60例因炎性泪点狭窄而主诉溢泪的患者。他们被分为两组:A组(30例患者)使用不含防腐剂的3.35mg/mL氢化可的松磷酸钠滴眼液与不含防腐剂的基于透明质酸钠、聚乙二醇和丙二醇的人工泪液联合治疗;B组(30例患者)仅使用相同的不含防腐剂的人工泪液治疗。纳入30名正常受试者以比较治疗前的解剖学参数。在开始治疗前,所有患者均接受眼前节评估,包括裂隙灯检查、眼压(IOP)测量、荧光素染料消失试验以及通过频域眼前节OCT测量外泪点直径(OPD)。在治疗后1个月和3个月的每次随访时重复所有评估,并通过简单评分问卷对患者对治疗结果的满意度进行主观评估。
两组治疗后泪点直径均显著增加(<0.0001);尽管A组的增宽幅度大于B组(为原始泪点大小的16.2%±8%,平均差值为28.933µm,P=0.0076)。A组对治疗结果的主观满意度也更高(70%±40%,卡方=0.0397)。
不含防腐剂的类固醇滴眼液和人工泪液联合使用可使炎性狭窄泪点显著增宽,并改善相关的溢泪症状。